Resistance mechanisms and overcoming strategies for CAR T-cell therapy in B-cell hematologic malignancies - Takeaways - MDSpire

Resistance mechanisms and overcoming strategies for CAR T-cell therapy in B-cell hematologic malignancies

  • By

  • Pupu Li

  • Xia Xue

  • Zisen Zhang

  • June 11, 2026

  • 0 min

Share

  • 1

    CAR T-cell therapy has significantly improved treatment outcomes for relapsed/refractory B-cell malignancies.

  • 2

    Resistance to CAR T-cell therapy arises from tumor-intrinsic factors, CAR T-cell dysfunction, and an immunosuppressive tumor microenvironment.

  • 3

    Innovative strategies to enhance CAR T-cell efficacy include multitarget CAR design, metabolic modulation, and tumor microenvironment remodeling.

  • 4

    FDA-approved CAR T-cell therapies have shown high complete remission rates in various B-cell malignancies, particularly B-ALL.

  • 5

    Challenges remain in applying CAR T-cell therapy to solid tumors due to their complex and hostile tumor microenvironments.

Original Source(s)

Resistance mechanisms and overcoming strategies for CAR T-cell therapy in B-cell hematologic malignancies

  • by Pupu Li, Xia Xue, Zisen Zhang

  • June 11, 2026

Related Content

Universal CD7-targeted CAR T-cell therapy in T-ALL: a promising bridge to transplant, but not without caveats—a critical reappraisal

A multicenter clinical study on transanal endoscopic sphincter-preserving resection of low rectal tumors

The future of neurosurgical oncology lies in cognitive neurosciences: understanding brain processing is much more valuable than surgical technology